Research and Development Collaborations (Details)	1 Months Ended	3 Months Ended		6 Months Ended
	Jun. 30, 2003 USD ($)	Jun. 30, 2022 USD ($)	Jun. 30, 2021 USD ($)	Jun. 30, 2022 USD ($) program	Jun. 30, 2021 USD ($)	Dec. 31, 2021 USD ($)	Feb. 29, 2020
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenues, net		$ 2,393,000	$ 2,286,000	$ 4,450,000	$ 4,475,000
Cost of royalty revenues		42,000	116,000	124,000	225,000
Accounts receivable		2,395,000		$ 2,395,000		$ 3,224,000
Number of program licensed | program				4
Royalties
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenues, net		2,474,000	2,348,000	$ 4,534,000	4,535,000
Genentech, Inc.
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Amount received for specified clinical development and regulatory objectives		59,000,000.0		59,000,000.0
Percentage of royalty rate decrease	2.00%
Cost of royalty revenues		100,000	100,000	100,000	200,000
Accounts receivable		2,400,000		2,400,000		3,200,000
Genentech, Inc. | Royalties
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenues, net		2,500,000	2,300,000	4,500,000	4,500,000
Genentech, Inc. | Maximum
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Eligible to receive contingent cash milestone payments (up to)	$ 115,000,000.0
Percentage of royalty on net sales	7.50%
Genentech, Inc. | Minimum
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Percentage of royalty on net sales	5.00%
Aurigene | IRAK4, PD1/VISTA, and PD1/TIM3 Programs
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Waived payment of milestone and other payments (up to)				42,500,000
Aurigene | Master Development and Manufacturing Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Prepaid expenses		0		0		0
Accrued expenses		0		0		$ 0
Aurigene | Master Development and Manufacturing Agreement | Research and Development Expense
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaborative arrangement payments agreement		$ 100,000	$ 400,000	$ 100,000	$ 800,000
Aurigene | Maximum
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Royalty fees receivable (as a percent)		10.00%		10.00%			10.00%
ImmuNext
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Semi-annual maintenance fee payments		$ 400,000		$ 400,000
ImmuNext | Maximum
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Maximum reimbursable expenses		300,000		300,000
Option exercise fee		20,000,000		20,000,000
Development milestone payments		4,600,000		4,600,000
Regulatory approval milestone payments		84,300,000		84,300,000
Sales milestone payments		$ 125,000,000		$ 125,000,000